GB201709459D0 - Treatment for migraine - Google Patents

Treatment for migraine

Info

Publication number
GB201709459D0
GB201709459D0 GBGB1709459.0A GB201709459A GB201709459D0 GB 201709459 D0 GB201709459 D0 GB 201709459D0 GB 201709459 A GB201709459 A GB 201709459A GB 201709459 D0 GB201709459 D0 GB 201709459D0
Authority
GB
United Kingdom
Prior art keywords
migraine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709459.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201709459(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Priority to GBGB1709459.0A priority Critical patent/GB201709459D0/en
Publication of GB201709459D0 publication Critical patent/GB201709459D0/en
Priority to SM20210037T priority patent/SMT202100037T1/it
Priority to JP2020519196A priority patent/JP7130739B2/ja
Priority to HUE18749124A priority patent/HUE053089T2/hu
Priority to RU2020100475A priority patent/RU2772278C2/ru
Priority to US16/622,785 priority patent/US11471434B2/en
Priority to PCT/IB2018/054676 priority patent/WO2018229738A1/en
Priority to ES18749124T priority patent/ES2847169T3/es
Priority to KR1020197038730A priority patent/KR102594130B1/ko
Priority to CA3067321A priority patent/CA3067321C/en
Priority to AU2018284330A priority patent/AU2018284330B2/en
Priority to MA49396A priority patent/MA49396B1/fr
Priority to LTEP18749124.6T priority patent/LT3638370T/lt
Priority to PL18749124T priority patent/PL3638370T3/pl
Priority to RS20210046A priority patent/RS61481B1/sr
Priority to PT187491246T priority patent/PT3638370T/pt
Priority to CN201880039532.2A priority patent/CN111093772B/zh
Priority to MX2019014784A priority patent/MX387909B/es
Priority to SI201830195T priority patent/SI3638370T1/sl
Priority to IL271211A priority patent/IL271211B2/en
Priority to MDE20200433T priority patent/MD3638370T2/ro
Priority to HRP20210108TT priority patent/HRP20210108T1/hr
Priority to DK18749124.6T priority patent/DK3638370T3/da
Priority to SG11201912146RA priority patent/SG11201912146RA/en
Priority to EP18749124.6A priority patent/EP3638370B1/en
Priority to BR112019026660-7A priority patent/BR112019026660B1/pt
Priority to ZA2019/08087A priority patent/ZA201908087B/en
Priority to CY20211100033T priority patent/CY1123860T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1709459.0A 2017-06-14 2017-06-14 Treatment for migraine Ceased GB201709459D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
EP18749124.6A EP3638370B1 (en) 2017-06-14 2018-06-25 Treatment of migraine with acetyl-leucine
BR112019026660-7A BR112019026660B1 (pt) 2017-06-14 2018-06-25 Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
PL18749124T PL3638370T3 (pl) 2017-06-14 2018-06-25 Leczenie migreny acetyloleucyną
RS20210046A RS61481B1 (sr) 2017-06-14 2018-06-25 Lečenje migrene acetil-leucinom
HUE18749124A HUE053089T2 (hu) 2017-06-14 2018-06-25 Migrén kezelése acetil-leucinnal
RU2020100475A RU2772278C2 (ru) 2017-06-14 2018-06-25 Лечение мигрени
US16/622,785 US11471434B2 (en) 2017-06-14 2018-06-25 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine
ES18749124T ES2847169T3 (es) 2017-06-14 2018-06-25 Tratamiento de migraña con acetil-leucina
KR1020197038730A KR102594130B1 (ko) 2017-06-14 2018-06-25 편두통 치료
CA3067321A CA3067321C (en) 2017-06-14 2018-06-25 Use of acetyle-leucine to prevent and/or treat migraine
AU2018284330A AU2018284330B2 (en) 2017-06-14 2018-06-25 Treatment for migraine
MA49396A MA49396B1 (fr) 2017-06-14 2018-06-25 Traitement de la migraine avec acétyl-leucine
LTEP18749124.6T LT3638370T (lt) 2017-06-14 2018-06-25 Migrenos gydymas acetilleucinu
SM20210037T SMT202100037T1 (it) 2017-06-14 2018-06-25 Trattamento dell'emicrania con acetil-leucina
JP2020519196A JP7130739B2 (ja) 2017-06-14 2018-06-25 片頭痛の治療
PT187491246T PT3638370T (pt) 2017-06-14 2018-06-25 Tratamento para hemicrania
CN201880039532.2A CN111093772B (zh) 2017-06-14 2018-06-25 偏头痛的治疗
MX2019014784A MX387909B (es) 2017-06-14 2018-06-25 Tratamiento para la migra?a
SI201830195T SI3638370T1 (sl) 2017-06-14 2018-06-25 Tretiranje migrene z acetil-levcinom
IL271211A IL271211B2 (en) 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine
MDE20200433T MD3638370T2 (ro) 2017-06-14 2018-06-25 Tratamentul migrenei cu acetil-leucină
HRP20210108TT HRP20210108T1 (hr) 2017-06-14 2018-06-25 Liječenje migrene s acetil-leucinom
DK18749124.6T DK3638370T3 (da) 2017-06-14 2018-06-25 Behandling af migræne med acetyl-leucin
SG11201912146RA SG11201912146RA (en) 2017-06-14 2018-06-25 Treatment For Migraine
ZA2019/08087A ZA201908087B (en) 2017-06-14 2019-12-05 Treatment for migraine
CY20211100033T CY1123860T1 (el) 2017-06-14 2021-01-18 Θεραπεια για την ημικρανια με ακετυλο-λευκινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine

Publications (1)

Publication Number Publication Date
GB201709459D0 true GB201709459D0 (en) 2017-07-26

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709459.0A Ceased GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine

Country Status (25)

Country Link
US (1) US11471434B2 (cg-RX-API-DMAC10.html)
EP (1) EP3638370B1 (cg-RX-API-DMAC10.html)
JP (1) JP7130739B2 (cg-RX-API-DMAC10.html)
KR (1) KR102594130B1 (cg-RX-API-DMAC10.html)
CN (1) CN111093772B (cg-RX-API-DMAC10.html)
AU (1) AU2018284330B2 (cg-RX-API-DMAC10.html)
CY (1) CY1123860T1 (cg-RX-API-DMAC10.html)
DK (1) DK3638370T3 (cg-RX-API-DMAC10.html)
ES (1) ES2847169T3 (cg-RX-API-DMAC10.html)
GB (1) GB201709459D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20210108T1 (cg-RX-API-DMAC10.html)
HU (1) HUE053089T2 (cg-RX-API-DMAC10.html)
IL (1) IL271211B2 (cg-RX-API-DMAC10.html)
LT (1) LT3638370T (cg-RX-API-DMAC10.html)
MA (1) MA49396B1 (cg-RX-API-DMAC10.html)
MD (1) MD3638370T2 (cg-RX-API-DMAC10.html)
MX (1) MX387909B (cg-RX-API-DMAC10.html)
PL (1) PL3638370T3 (cg-RX-API-DMAC10.html)
PT (1) PT3638370T (cg-RX-API-DMAC10.html)
RS (1) RS61481B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201912146RA (cg-RX-API-DMAC10.html)
SI (1) SI3638370T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100037T1 (cg-RX-API-DMAC10.html)
WO (1) WO2018229738A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201908087B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712239A (zh) * 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
ES2327684T3 (es) * 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
MXPA06003123A (es) * 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
MX376862B (es) 2010-11-09 2025-03-07 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
PT3600276T (pt) 2017-03-28 2023-07-11 Intrabio Ltd Beta-histina, ou um seu sal farmaceuticamente aceitável, e um inibidor da monoamina oxidase, para utilização no tratamento ou prevenção de um ou mais sintomas de vertigem num indivíduo
US11793782B2 (en) 2017-10-18 2023-10-24 Intrabio Limited Therapeutic agents for neurodegenerative diseases
EP3697406A1 (en) 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RS65663B1 (sr) 2018-02-15 2024-07-31 Intrabio Ltd Acetil leucin za upotrebu u lečenju sindroma nemirnih nogu
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712239A (zh) * 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂

Also Published As

Publication number Publication date
KR102594130B1 (ko) 2023-10-24
AU2018284330A1 (en) 2020-01-02
CA3067321A1 (en) 2018-12-20
JP2020526575A (ja) 2020-08-31
ES2847169T3 (es) 2021-08-02
MD3638370T2 (ro) 2021-04-30
CN111093772B (zh) 2023-11-03
IL271211B2 (en) 2024-01-01
RU2020100475A3 (cg-RX-API-DMAC10.html) 2021-10-22
DK3638370T3 (da) 2021-01-25
HUE053089T2 (hu) 2021-06-28
AU2018284330B2 (en) 2024-03-14
SI3638370T1 (sl) 2021-04-30
WO2018229738A1 (en) 2018-12-20
ZA201908087B (en) 2024-11-27
BR112019026660A2 (pt) 2020-07-14
HRP20210108T1 (hr) 2021-03-19
SG11201912146RA (en) 2020-01-30
RS61481B1 (sr) 2021-03-31
RU2020100475A (ru) 2021-07-14
MA49396A (fr) 2020-04-22
CN111093772A (zh) 2020-05-01
EP3638370B1 (en) 2020-11-11
SMT202100037T1 (it) 2021-03-15
US20200253905A1 (en) 2020-08-13
LT3638370T (lt) 2021-03-25
KR20210013518A (ko) 2021-02-04
MA49396B1 (fr) 2021-03-31
MX2019014784A (es) 2021-11-16
IL271211A (en) 2020-01-30
EP3638370A1 (en) 2020-04-22
PT3638370T (pt) 2021-01-26
JP7130739B2 (ja) 2022-09-05
CY1123860T1 (el) 2022-05-27
IL271211B1 (en) 2023-09-01
PL3638370T3 (pl) 2021-05-17
US11471434B2 (en) 2022-10-18
MX387909B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
IL291153A (en) Methods for treating or preventing migraine headaches
IL265343A (en) Treatment of persistent migraine
GB201608885D0 (en) Treatment
GB2567616B (en) Treatment method
GB201811679D0 (en) Treatment apparatus
GB2571601B (en) Treatment method
SG11202001806TA (en) Treatment method
IL271211A (en) Migraine treatment
SG10201913381PA (en) Treatment apparatus
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
GB201718985D0 (en) Treatment
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201617380D0 (en) Treatment for Osteoarthritis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)